文献速递脑血管病

氯吡格雷疗效取决于CYP2C19基因型与风险分层

Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
PubMed 文献 · Ann Neurol · 2019-07-18

该研究纳入2933例轻型卒中或TIA患者,比较氯吡格雷联合阿司匹林与单用阿司匹林对1年卒中复发的影响。总体LoFA携带者无显著获益,但高风险LoFA携带者联合治疗显著降低复发。

要点

  • LoFA携带者总体未从双抗治疗中显著获益
  • 高风险(ESRS≥3)LoFA携带者双抗治疗显著获益
  • CYP2C19基因型与风险分层存在显著交互作用

核心结论

  • LoFA携带者总体未从双联抗血小板治疗中显著获益,但高风险LoFA携带者显著获益。

研究设计与样本

  • 研究纳入2933例轻型卒中或TIA患者,比较氯吡格雷联合阿司匹林与单用阿司匹林,按CYP2C19基因型和ESRS分层。

主要发现

  • LoFA携带者中双抗组与单药组卒中复发率分别为11.2%和13.3%,HR=0.83(95%CI 0.64~1.09)。
  • LoFA携带者低风险亚组HR=1.00(95%CI 0.70~1.42)。
  • LoFA携带者高风险亚组HR=0.63(95%CI 0.41~0.97)。
  • LoFA非携带者低风险亚组HR=0.62(95%CI 0.40~0.96)。
  • LoFA非携带者高风险亚组HR=0.52(95%CI 0.31~0.88),交互作用P=0.021。

关键数值与推荐

  • LoFA携带者定义为携带*2或*3功能缺失等位基因。
  • 低风险定义为ESRS<3,高风险定义为ESRS≥3。
  • 主要结局为1年卒中复发。

临床怎么用

  • 对轻型卒中或TIA患者,可结合CYP2C19基因型与ESRS评估双抗治疗获益。
  • 高风险LoFA携带者可能从氯吡格雷联合阿司匹林治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients. The purpose of this study was to find the potential subgroups that benefit from DAT. We aimed to compare the efficacy of clopidogrel-aspirin therapy with that of aspirin therapy in MS/TIA patients stratified by CYP2C19 genotype and risk profiles. METHODS: CYP2C19 loss-of-function allele (LoFA) carriers were defined as patients with LoFA of either *2 or *3. Low- and high-risk profile was defined as Essen Stroke Risk Score (ESRS) <3 and ≥3, respectively. Stroke recurrence at 1 year was considered primary outcome. RESULTS: Of a total 2,933 MS/TIA patients, there were 1,726 (58.8%) LoFA carriers and 1,068 (36.4%) patients at high risk (ESRS ≥3). No significant difference for stroke recurrence between the clopidogrel-aspirin group and aspirin alone group was found in LoFA carriers (11.2% vs 13.3%, hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.64~1.09). In stratified analyses by CYP2C19 genotype and ESRS, HRs (95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 1.00 (0.70~1.42), 0.63 (0.41~0.97), 0.62 (0.40~0.96), and 0.52 (0.31~0.88) among subgroups of LoFA carriers at low risk, LoFA carriers at high risk, LoFA noncarriers at low risk, and LoFA noncarriers at high risk, respectively, with p = 0.021 for interaction. INTERPRETATION: Overall, LoFA carriers do not benefit from DAT, but there is significant benefit for LoFA carriers who are at high risk. The benefit of clopidogrel in Chinese MS/TIA patients depends on CYP2C19 genotype and risk profile. ANN NEUROL 2019;86:419-426.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Xu J, Wang A, Wangqin R, et al. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. Ann Neurol. 2019. PMID: 31237713. doi:10.1002/ana.25535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。